Annual Report

Overview

The report covers EQL Pharma's 2024/25 financial year and highlights group net sales of SEK 373.5 million, up 41%. It reports 10 product launches, five approvals and 20 products added to the pipeline, alongside a Nasdaq Stockholm main-market listing and the acquisition of four niche original products. Sustainability content identifies seven UN Sustainable Development Goals and describes a goal to reduce greenhouse-gas emissions by 2027.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024-2025
Period: 1 April 2024 – 31 March 2025
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services